1. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116–29.

2. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebocontrolled phase 2 study. Lancet Neurol 2014;13:987–96.

3. Seto JT, Bengtsson NE, Chamberlain JS. Therapy of genetic disorders-novel therapies for Duchenne muscular dystrophy. Curr Pediatr Rep 2014;2:102–12.

4. Bakker JP, de Groot IJ, Beckerman H, de Jong BA, Lankhorst GJ. The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin Rehabil 2000;14:343–59.

5. Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012;23:675–87.

6. Sethi PK. The Knud Jansen lecture. Technological choices in prosthetics and orthotics for developing countries. Prosthet Orthot Int 1989;13:117–24.

7. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy. Part 2. Implementation of multidisciplinary care. Lancet Neurol 2010;9:177–89.

8. Loos GP, Smith RG, Roseman C. Probable future funding priorities in maternal and child health: a modified Delphi National Survey. J Health Polit Policy Law 1985;9:683–93.

9. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214–23.

10. Hidecker MJ, Paneth N, Rosenbaum PL, Kent RD, Lillie J, Eulenberg JB, et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011;53:704–10.

11. Eliasson AC, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall AM, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006;48:549–54.

12. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13–21.

13. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–5. 14. Hocking C, Williams M, Broad J, Baskett J. Sensitivity of Shah, Vanclay and Cooper’s modified Barthel Index. Clin Rehabil 1999;13:141–7.

15. Lue YJ, Su CY, Yang RC, Su WL, Lu YM, Lin RF, et al. Development and validation of a muscular dystrophy-specific functional rating scale. Clin Rehabil 2006;20:804–17.

16. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006;16:417–26.

17. van den Beld WA, van der Sanden GA, Feuth T, Janssen AJ, Sengers RC, Verbeek AL, et al. A new motor performance test in a prospective study on children with suspected myopathy. Dev Med Child Neurol 2006;48:739–43.

18. Ostensjo S, Bjorbaekmo W, Carlberg EB, Vollestad NK. Assessment of everyday functioning in young children with disabilities: an ICF-based analysis of concepts and content of the Pediatric Evaluation of Disability Inventory (PEDI). Disabil Rehabil 2006;28:489–504.

19. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186–97.

20. Ottenbacher KJ, Taylor ET, Msall ME, Braun S, Lane SJ, Granger CV, et al. The stability and equivalence reliability of the functional independence measure for children (WeeFIM). Dev Med Child Neurol 1996;38:907–16.

21. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–86.

22. Jung IY, Chae JH, Park SK, Kim JH, Kim JY, Kim SJ, et al. The correlation analysis of functional factors and age with Duchenne muscular dystrophy. Ann Rehabil Med 2012;36:22–32.

23. Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 2016;87:149–55.

24. Kinali M, Messina S, Mercuri E, Lehovsky J, Edge G, Manzur AY, et al. Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study. Dev Med Child Neurol 2006;48:513–8.

25. Kinali M, Main M, Eliahoo J, Messina S, Knight RK, Lehovsky J, et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol 2007;11:160–6.

26. Mullender M, Blom N, De Kleuver M, Fock J, Hitters W, Horemans A, et al. A Dutch guideline for the treatment of scoliosis in neuromuscular disorders. Scoliosis 2008;3:14.

27. Weis R. Introduction to abnormal child and adolescent psychology. 2nd ed. Los Angeles: Sage Publications; 2014. 28. AAIDD User’s Guide Work Group. User’s guide: to accompany the 11th edition of Intellectual disability: definition, classification, and systems of supports: applications for clinicians, educators, organizations providing supports, policymakers, family members and advocates, and health care professionals. Washington: American Association on Intellectual and Developmental Disabilities; 2012. 29. Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci 2002;57:M470–2.